HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness

HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness

HER2 overexpression/amplification occurs in 15–20% of breast cancers (BCs) and identifies a highly aggressive BC subtype. Recent clinical progress has increased the cure rates of limited-stage HER2-positive BC and significantly prolonged overall survival in patients with advanced disease; however, d...

Full description

Bibliographic Details
Main Authors: Serenella M. Pupa, Francesca Ligorio, Valeria Cancila, Alma Franceschini, Claudio Tripodo, Claudio Vernieri, Lorenzo Castagnoli
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
breast cancer
cancer stem cells
full-length HER2
d16HER2 splice variant
p95HER2
stemness signaling pathways
Online Access:https://www.mdpi.com/2072-6694/13/19/4778

Internet

https://www.mdpi.com/2072-6694/13/19/4778

Similar Items